



April 07, 2026

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

Symbol: LUPIN

BSE Limited

P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Scrip Code: Equity - 500257

Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

We are pleased to enclose a Press Release titled "Lupin Announces the Approval of Dapagliflozin Tablets in the United States".

The same is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**AMIT KUMAR
GUPTA**

Digitally signed by AMIT KUMAR GUPTA
DN: c=IN, st=Maharashtra,
2.5.4.20=f72cf0252d2a7e595b45b84659bdca28c8f26a939bb358
35a1692a23729a3, postalCode=400705, street=C701
Shivdharshan CHS Ltd Sector 16 Plot No5 Navi Mumbai,
pseudonym=d3a468d0d03546efabff2a7cb7a8aae, title=7875,
serialNumber=de9bbd80d8994e4be9f0dd2399144eba7e782d70
287df6aad1994f0b522fa08a, o=Personal, cn=AMIT KUMAR
GUPTA
Date: 2026.04.07 21:16:11 +05'30'

**AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS -15754)**

Encl.: a/a.

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

info@lupin.com | www.lupin.com

Lupin Announces the Approval of Dapagliflozin Tablets in the United States

Mumbai, India, Naples, Fla, APRIL 7, 2026: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin Tablets, 5 mg and 10 mg.

The U.S. FDA has approved Lupin's Dapagliflozin Tablets, 5 mg and 10 mg, as bioequivalent to Farxiga® for the indications in the approved labeling.

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

To know more, visit www.lupin.com or follow us on LinkedIn <https://www.linkedin.com/company/lupin>

For further information or queries, please contact

Rajalakshmi Azariah

Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com

Elise Titan

Director – U.S. Communications, Lupin
elisetitan@lupin.com

***Safe Harbor Statement**

Farxiga is a registered trademark of AstraZeneca AB.